



MEDIA RELEASE
For release January 10th, 2011

INNOVASCREEN SECURES PATENT COVERING FUSOGENIX INTRACELLULAR DELIVERY PLATFORM

HALIFAX, NOVA SCOTIA, CANADA – January 11, 2011 -- Innovascreen, Inc., a private biotechnology company, announces today the U.S. Patent Office issued United States Patent #7,851,595 to Innovascreen for novel fusogenic proteins and their uses. These fusogenic proteins are a key component of Innovascreen's intracellular drug delivery platform, Fusogenix.

“Our Fusogenix Platform can dramatically increase the intracellular concentration of a wide variety of therapeutics,” said Dr. John Lewis, President and CEO of Innovascreen. “Receipt of this patent is an important milestone for Innovascreen as we continue the development of this first-in-class drug delivery system.”

Innovascreen has filed several patent applications associated with its intracellular drug delivery platform, which actively bypasses the endocytic pathway and enables the delivery of therapeutics directly into the cytoplasm where they can generate an optimal effect.

“This new patent, part of an ongoing program to protect the use of novel fusogenic proteins and peptides, provides protection in a key market,” added Jeff Skinner, Director of Business Development at Innovascreen. “This extends our coverage internationally and gives us a solid platform from which to launch partnering efforts for our intracellular therapeutic delivery system.”

About The Fusogenix Platform

Fusogenix is a liposomal drug delivery platform that allows access to the 1000's of intracellular drug targets by inducing fusion with the plasma membrane. Effectively bypassing the endocytic pathway, therapeutics are delivered, intact and unmodified, directly into the cytoplasm where they can generate an optimal effect. The technology easily incorporates into optimized liposomal formulations and drastically

increases intracellular concentrations of a wide range of therapeutic types including: small molecules, biologics and siRNA

About Innovascreen

With two platform technologies under management, Innovascreen is an ideal partner for an organization involved in early stage preclinical development of therapeutic candidates. The Avian System for Evaluating Therapeutics (ASET) Platform allows our clients and partners to screen compound libraries and validates lead candidates for further investment, using methods that are faster, better and cheaper than most other available options. Fusogenix is an advanced intracellular drug delivery platform with a unique mechanism of action that drastically increases the intracellular delivery of therapeutic cargos. Innovascreen is a privately held company, headquartered in Nova Scotia, Canada. For more information, please visit www.innovascreen.com

Contact:

Jeff Skinner,
Director, Business Development, Innovascreen, Inc
(902) 482-3832 x 7, jeff.skinner@innovascreen.com